(Q42614878)

English

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

scientific article published on 19 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

1 reference

based on heuristic

inferred from title

Joseph Gligorov

2

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Lesley Fallowfield

13

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Lesley Fallowfield

14

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

object named as

Ann Knoop

6

0 references

Peter Barrett-Lee

object named as

Peter Barrett-Lee

4

0 references

Vladimir Semiglazov

object named as

Vladimir Semiglazov

8

0 references

Giuseppe Curigliano

object named as

Giuseppe Curigliano

7

0 references

author name string

Xavier Pivot

1

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Volkmar Müller

3

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Sunil Verma

5

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Guillermo López-Vivanco

9

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Valerie Jenkins

10

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Nana Scotto

11

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Stuart Osborne

12

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PrefHer Study Group

15

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

publication date

19 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

962-970

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970383-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70383-8

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42614878&oldid=1962859827"